Tag: Reversal agent

Multiple meta-analyses have shown that sugammadex reverses neuromuscular blockade significantly faster and more reliably than neostigmine. This major clinical advantage is at the heart of the discussion surrounding **why is sugammadex better than neostigmine** for patient safety and surgical efficiency.

Since its FDA approval in 2015, sugammadex has revolutionized the practice of anesthesia by offering a rapid and predictable reversal of specific muscle relaxants. Sugammadex is a selective relaxant binding agent (SRBA) that reverses the effects of the steroidal, non-depolarizing neuromuscular blocking agents rocuronium and vecuronium. Unlike older reversal agents, it works by encapsulating the drug molecules, preventing them from interacting with nerve receptors.

Residual neuromuscular blockade, a common issue after surgery, is estimated to occur in 30% to 60% of patients in the recovery room. The emergence of sugammadex has revolutionized anesthetic practice by providing a rapid and effective solution to this problem. Unlike traditional reversal agents, which act on different biochemical pathways, **how does sugammadex work** via a unique mechanism of action known as encapsulation.